Interlaboratory Study for Characterizing Monoclonal Antibodies by Top-Down and Middle-Down Mass Spectrometry
- 19 August 2020
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of the American Society for Mass Spectrometry
- Vol. 31 (9) , 1783-1802
Abstract
The Consortium for Top-Down Proteomics (www.topdownproteomics.org) launched the present study to assess the current state of top-down mass spectrometry (TD MS) and middle-down mass spectrometry (MD MS) for characterizing monoclonal antibody (mAb) primary structures, including their modifications. To meet the needs of the rapidly growing therapeutic antibody market, it is important to develop analytical strategies to characterize the heterogeneity of a therapeutic product’s primary structure accurately and reproducibly. The major objective of the present study is to determine whether current TD/MD MS technologies and protocols can add value to the more commonly employed bottom-up (BU) approaches with regard to confirming protein integrity, sequencing variable domains, avoiding artifacts, and revealing modifications and their locations. We also aim to gather information on the common TD/MD MS methods and practices in the field. A panel of three mAbs was selected and centrally provided to twenty laboratories worldwide for the analysis: Sigma mAb standard (SiLuLite), NIST mAb standard, and the therapeutic mAb Herceptin (trastuzumab). Various MS instrument platforms and ion dissociation techniques were employed. The present study confirms that TD/MD MS tools are available in laboratories worldwide, and provide complementary information to the BU approach that can be crucial for comprehensive mAb characterization. The current limitations, as well as possible solutions to overcome them, are also outlined. A primary limitation revealed by the results of the present study is that the expert knowledge in both experiment and data analysis is indispensable to practice TD/MD MS.Keywords
Funding Information
- Division of Chemistry (CHE1402753)
- Welch Foundation (F-1155)
- National Center for Research Resources (S10RR028893)
- Thermo Fisher Scientific
- NIH Office of the Director (S10 OD018504)
- H2020 Future and Emerging Technologies (829157)
- National Institute of General Medical Sciences (GM037537, GM108569, R01GM103479)
- Bruker Corporation
- Genovis AB
This publication has 108 references indexed in Scilit:
- Extending the Isotopically Resolved Mass Range of Orbitrap Mass SpectrometersAnalytical Chemistry, 2013
- Glycoproteomic Analysis of AntibodiesMolecular & Cellular Proteomics, 2013
- Glycan variability on a recombinant IgG antibody transiently produced in HEK-293E cellsNew Biotechnology, 2012
- Unit Mass Baseline Resolution for an Intact 148 kDa Therapeutic Monoclonal Antibody by Fourier Transform Ion Cyclotron Resonance Mass SpectrometryAnalytical Chemistry, 2011
- Top‐down protein characterization facilitated by ion/ion reactions on a quadrupole/time of flight platformProteomics, 2010
- An Integrated Top-Down and Bottom-Up Strategy for Broadly Characterizing Protein Isoforms and ModificationsJournal of Proteome Research, 2009
- Mass spectrometry for structural characterization of therapeutic antibodiesMass Spectrometry Reviews, 2008
- Rational Selection of the Optimum MALDI Matrix for Top-Down Proteomics by In-Source DecayAnalytical Chemistry, 2007
- Rapid sequencing and disulfide mapping of peptides containing disulfide bonds by using 1,5‐diaminonaphthalene as a reductive matrixJournal of Mass Spectrometry, 2005
- Primary Sequence Information from Intact Proteins by Electrospray Ionization Tandem Mass SpectrometryScience, 1990